NYMXF Stock Price, Chart, Stats & News

Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma.